Page 6 - Johan Dighed News Today

Karolinska Development’s portfolio company OssDsign raises SEK 270 million through an oversubscribed rights issue Nachrichtenquelle: globenewswire  |  12.05.2021, 13:28  |  41   |  0  STOCKHOLM, SWEDEN – May 12, 2021. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces today that its portfolio company OssDsign completed a successful rights issue of shares...

(0) STOCKHOLM, SWEDEN - May 12, 2021. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces today that its portfolio company OssDsign completed a successful rights issue of shares with preferential rights for the companys existing shareholders to a value of SEK 240 million. The rights issue was oversubscribed, to a rate of 185%, and thus the Board of Directors decided to carry out a directed new issue of shares without preferential rights for existing owners through an over-allotment opt...

Investegate announcements from Karolinska Development AB (pub, Karolinska Development’s portfolio company OssDsign raises SEK 270 million through an oversubscribed rights issue

(0) STOCKHOLM, SWEDEN - April 9, 2021. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to Aprea Therapeutics drug candidate eprenetapopt for the treatment of acute myeloid leukemia (AML). KDev Investments, a company jointly owned by Karolinska Development and Rosetta Capital, holds 8 percent of the shares in Aprea Therapeutics, which is listed on Nasdaq Global Select Market in the USA. Eprene...

(0) STOCKHOLM, SWEDEN - April 6, 2021. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces today that its portfolio company Dilafor has completed the inclusion of patients to its study of tafoxiparin - a drug candidate with the potential to shorten the delivery time in women receiving treatment to initiate labor. About one in four of all pregnant women receive treatment to induce labor, but more than half of these treatments fail. This leads to a prolonged birth process that increases ...

(1) STOCKHOLM, SWEDEN - March 10, 2021. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces today that its portfolio company Modus Therapeutics is preparing a clinical development program of its drug candidate sevuparin in patients suffering from sepsis/septic shock, and possibly also other severe inflammatory conditions arising in conjunction with major trauma, surgery, autoimmunity and viral infections. Modus Therapeutics expects to start the first clinical trial in this new indicati...

Swedish STOCKHOLM, SWEDEN – March 3, 2021. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces today that its portfolio company, Forendo Pharma, has successfully completed a Phase 1 program for FOR-6219 – a candidate drug aimed for the treatment of endometriosis. Based on the positive results generated in this program, Forendo Pharma is now preparing a Phase 2 study in the US. The randomized, double-blind, placebo-controlled Phase 1 program of FOR-6219 included 66 healthy pre- and ...

Karolinska Development AB (pub Karolinska Development’s portfolio company OssDsign announces a fully guaranteed rights issue and launches new corporate strategy Karolinska Development’s portfolio company OssDsign announces a fully guaranteed rights issue and launches new corporate strategy STOCKHOLM, SWEDEN – March 2, 2021. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces today that its portfolio company OssDsign has decided to carry out a fully guaranteed rights issue of SEK ...

Karolinska Development appoints Johan Dighed as Deputy CEO STOCKHOLM, SWEDEN – February 26, 2021. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces today that Johan Dighed has been appointed as Deputy CEO. He takes up the position immediately and will, in addition to his new duties, continue to hold his current role as the companys General Counsel. Johan Dighed was appointed as General Counsel at Karolinska Development in May 2020. He has a background from SEB, one of the leading N...

STOCKHOLM, SWEDEN - February 26, 2021. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces today that Johan Dighed has been appointed as Deputy CEO. He takes up the position immediately and will